Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyHighmark Blueshield NENY Evenity Prior Auth | Open…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Evenity (romosozumab) — Outpatient Injectable Authorization Criteria

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Authorization form and clinical questionnaire for outpatient administration of Evenity (romosozumab) under the medical benefit; intended for providers requesting prior authorization for Highmark BlueShield members in the applicable service region.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyEvenity (romosozumab) — Outpatient Injectable Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrior authorization must be requested using the Evenity Authorization Request Form and faxed to the plan with required clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12lifetime Evenity doses referenced
    833-581-1861authorization fax
    T-score, DEXA, bisphosphonate history

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    required clinical data

    Coverage & Authorization Criteria

    Submission requirements for authorization

    Authorization assessment requires submission of ALL requested clinical items; approval is contingent on review of the documentation provided.

    Required submission items: Provider must supply member identifiers (name, date of birth, member ID), ordering/attending provider and facility information (names and NPIs), requested Drug Name and HCPCS code, requested start date of service, ICD-10 diagnosis code(s), most recent DEXA T-score(s) with date of scan, documentation of trial and failure of at least one bisphosphonate (including which agent(s), duration of therapy, and reason for failure or contraindication), history of osteoporotic fracture with site and date, FRAX results if used (10-year major osteoporotic fracture and hip fracture risks), whether Evenity will be given in combination with parathyroid hormone analogs or RANKL inhibitors, member menopausal status, number of prior Evenity doses received and date of last Evenity injection, number of Evenity doses being requested, and accompanying supporting clinical records (attachments).

    Form explicitly requests these items to evaluate authorization

    The authorization form explicitly asks whether Evenity will be given concurrently with other anabolic or antiresorptive agents. Specifically, providers must indicate if the member will receive Evenity in combination with parathyroid hormone analogs (for example, Forteo or Tymlos) and/or RANKL inhibitors (for example, Prolia or Xgeva). This information is collected to inform the clinical review; the form queries concomitant use rather than describing separate coverage rules for combination therapy.

    The document does not list specific scenarios that are categorically not medically necessary. However, the form emphasizes tracking cumulative lifetime exposure: providers must state whether the member still needs to complete twelve (12) doses per lifetime, report how many doses are being requested, and provide the number and date of any prior Evenity injections. Completion of the 12-dose lifetime allowance is a required element of the authorization submission and will be used during review.

    Billing and Coding

    Requested HCPCSHCPCS
    HCPCSDrug Name and HCPCS Code (provider to supply specific code)
    Diagnosis codesICD-10
    ICD-10ICD10 Diagnosis Code(s) (provider to supply specific code(s))
    Lifetime Evenity doses
    Lifetime doses12
    Source contextForm asks whether the member still needs to complete twelve (12) doses per lifetime and requests number of previous doses received.
    Action for providerReport number of previous Evenity doses and date of last injection on the authorization form.

    Provider Submission & Documentation Actions

    Prior Authorization

    Prior authorization required — use form and fax

    Submit a prior authorization using the Outpatient Medical Injectable EVENITY Authorization Request Form and fax it to 833-581-1861. Include the Drug Name and the HCPCS code on the form and indicate the number of doses being requested and how many prior Evenity doses the member has received.

    • Fax number: 833-581-1861
    • Include Drug Name and HCPCS Code on the form
    • State number of doses requested and number of prior Evenity doses received
    Step Therapy

    Document prior bisphosphonate trial (agent, duration, reason)

    Document that the member has tried and failed at least one bisphosphonate, specifying which agent(s), duration of therapy, and the reason for failure or contraindication.

    • List which bisphosphonate(s) were used

    Background

    Evenity (romosozumab) is an injectable anti-osteoporosis agent. The authorization form requests objective clinical data commonly used to evaluate appropriateness for Evenity, including recent DEXA T-scores with dates, fracture history, prior osteoporosis therapy (e.g., bisphosphonate) trial details, FRAX results if used, and documentation of prior Evenity dosing. These items support the typical rationale for authorization: demonstration of osteoporosis severity, prior treatment attempts or contraindications, fracture risk assessment, and confirmation of remaining lifetime doses.

    Definitions & Clinical Tools

    Lifetime dose definition
    DefinitionCompleted 12 injections per lifetime
    Required documentationProvide number of previous doses and date of last Evenity injection; attach pertinent clinical information.
    FRAX (10-year fracture risk tool)
    DefinitionFRAX is a clinical risk-estimate tool for 10-year fracture risk (major osteoporotic fracture and hip fracture)
    Form promptWas a FRAX calculator used? If so, provide the member's 10-year risk of major osteoporotic fracture and 10-year risk of hip fracture.
    Use in authorizationInclude FRAX scores on the authorization form if used to support fracture risk assessment.
    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyEvenity (romosozumab) — Outpatient Injectable Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrior authorization must be requested using the Evenity Authorization Request Form and faxed to the plan with required clinical documentation.
    SourceLink
    On This Page
    Coverage & Authorization CriteriaBilling and CodingProvider Submission & Documentation ActionsBackgroundDefinitions & Clinical Tools
  1. Provide duration of each bisphosphonate trial
  2. State reason for failure or any contraindication to bisphosphonate therapy
  3. Documentation Required

    Attach required documentation and verify benefits

    Attach a completed authorization form with member demographics, ordering/provider and facility NPIs, the Drug Name and HCPCS code, ICD-10 diagnosis code(s), recent DEXA T-scores with the DEXA date, bisphosphonate trial details (including duration and reason or contraindication), fracture history with dates, FRAX results if used, concomitant osteoporosis therapies, number of prior Evenity doses and number of doses requested, and supporting clinical records. Verify member eligibility and benefits.

    • Member name, date of birth, member ID
    • Ordering/attending provider name and NPI; facility/vendor name and facility NPI
    • Drug Name and HCPCS Code; ICD-10 diagnosis code(s)
    • Recent DEXA T-score(s) with date of scan
    • Bisphosphonate trial details: agents, duration, reason for failure or contraindication
    • Fracture history (site and date) and FRAX scores if used
    • Number of prior Evenity doses, date of last injection, and number of doses requested
    • Attach all pertinent clinical information and verify eligibility/benefits
    Denial Risk

    Risk of denial or delay if clinical documentation is incomplete

    Failure to provide requested clinical information — such as recent DEXA with T-scores and date, details of bisphosphonate trials (agents, duration, reason for failure or contraindication), fracture history, FRAX results, prior Evenity dose history, and attachments — may delay or result in denial of the authorization.

    • Missing DEXA T-scores and scan date
    • Missing bisphosphonate trial duration or reason for failure/contraindication
    • Absent fracture site/date or FRAX results
    • No documentation of prior Evenity doses or missing clinical attachments